Abstract
BackgroundPatients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, the question of whether proton pump inhibitor (PPI) intake contributes...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have